Skip to main content
Annual Report
2018

Siegfried, a worldwide leading CDMO, produces active pharmaceutical ingredients (APIs), intermediates and finished products from a single source. Our core competence is process development and the integration of complementary chemical and pharmaceutical capabilities in a single business model. 

Report

Dear Shareholders

Siegfried Group reported a good result for the 2018 financial year, the best in its corporate history. Sales amounted to 794.3 million Swiss francs, corresponding to a growth of 5.8 percent. Earnings before interest, taxes, depreciation and amortization (EBITDA) grew by 14.5% to 127.4 million Swiss francs, corresponding to an EBITDA margin of 16.0 percent (2017: 14.8 percent). Earnings, therefore, again grew faster than sales. Siegfried achieved a significantly higher net profit of 57.5 million Swiss francs (2017: CHF 40.8 million), an increase of 40.9%.

Dr. Andreas Casutt
Chairman

Dr. Wolfgang Wienand
Chief Executive Officer

Strategy

Key figures

Net sales
794.3
million Swiss francs
Change over previous year:
+5.8%
Change 
EBITDA
127.4
million Swiss francs
Change over previous year:
+14.5%.
Change 
EBIT
77.8
million Swiss francs
Change over previous year:
+25.7%
Change 

Information for investors